OTLK

Outlook Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website outlooktherapeutics.com
Employees(FY) 24
ISIN US69012T3059

Performance

-59.64%

-66.45%

-72.38%

-71.29%

-74.24%

YTD

-76.76%

Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Advanced Technical Analysis

Technical Analysis of OTLK 2024-12-02

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 43 suggesting a neutral stance, and a Technical Score of 26 reinforcing the overall bearish outlook. This combination signals caution for potential investors as the market appears to be st...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of OTLK

Stock Rank

Recent News & Updates

2024-11-29 16:50
Outlook Therapeutics price target lowered to $9 from $50 at BTIG(Yahoo Finance)
2024-11-26 22:08
Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial(Yahoo Finance)
2024-11-26 22:07
Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial(Yahoo Finance)
2024-11-26 20:27
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?(Yahoo Finance)
2024-11-26 17:50
Outlook Therapeutics Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial(Globenewswire)
2024-11-05 19:05
Outlook Therapeutics to Present at the Guggenheim Healthcare Innovation Conference(Globenewswire)
2024-10-16 21:00
Outlook Therapeutics Participates in a Virtual Investor CEO Connect Segment(Globenewswire)
2024-09-15 20:05
Outlook Therapeutics to Participate in the Virtual Investor Closing Bell Series(Globenewswire)
2024-09-12 21:05
Outlook Therapeutics Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series(Globenewswire)
2024-09-03 20:35
Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial(Globenewswire)
2024-09-02 20:45
Outlook Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-14 18:20
Q3 2024 Outlook Therapeutics Inc Earnings Call(Yahoo Finance)
2024-08-13 19:05
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update(Globenewswire)
2024-08-11 21:05
Outlook Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference(Globenewswire)
2024-08-08 19:16
Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now?(Yahoo Finance)
2024-08-06 20:35
Outlook Therapeutics to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast(Globenewswire)
2024-07-29 21:10
Outlook Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2024(Globenewswire)
2024-07-07 20:35
Outlook Therapeutics Announces UK MHRA Marketing Authorization of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD(Globenewswire)
2024-06-24 19:30
3 Undervalued Gems Set to Soar 1,000% by 2026(Investorplace)
2024-06-16 20:00
Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024(Accesswire)
2024-06-11 22:00
Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series(Accesswire)
2024-06-10 21:05
Outlook Therapeutics to Present at the Virtual Investor Pitch Conference(Globenewswire)
2024-06-09 20:00
JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024(Accesswire)
2024-06-05 22:30
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor 'What This Means' Segment Hosted by JTC Team(Accesswire)
2024-05-27 20:05
Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD(Globenewswire)
2024-05-16 16:27
Q2 2024 Outlook Therapeutics Inc Earnings Call(Yahoo Finance)
2024-05-15 10:53
OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024(Investorplace)
2024-05-15 05:00
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update(Globenewswire)
2024-05-12 23:18
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK(Yahoo Finance)
2024-05-12 20:50
Outlook Therapeutics Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.